Navigation Links
LeMaitre Vascular Announces Changes to Its Executive Management Team
Date:4/10/2008

BURLINGTON, Mass., April 10 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) today announced the departure of Kevin D. Kelly, Senior Vice President, North American Sales, to pursue other business opportunities and the appointment of Robert V. Linden to Vice President, North American Sales.

Mr. Linden has approximately six years North American sales experience with LeMaitre Vascular. He joined LeMaitre Vascular in July 2002 as a Sales Representative and has served in positions of increasing responsibility within the North American organization. Since January 2008, he has served as Director of Sales for the Eastern United States and Canada, supervising three of the company's five North American sales regions. From 2005 through 2007, Mr. Linden served as Regional Sales Manager. Prior to LeMaitre Vascular, Mr. Linden served as a sales representative at several medical device companies, including Vasca, Inc., Atrium Medical Corporation, Active Medical, Inc., and DePuy Orthopedics, Inc. Mr. Linden holds a B.A. in Marketing from The Pennsylvania State University.

LeMaitre Vascular Chairman and Chief Executive Officer George W. LeMaitre stated, "We want to thank Kevin Kelly for his contributions and we wish him the best. We are thrilled to promote Rob Linden to the position of Vice President, North American Sales. I have watched Rob succeed at our company in positions of increasing responsibility over the past six years. We believe he will build on this experience to provide effective leadership for our North American sales organization."

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803.

Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge, these forward-looking statements are neither promises nor guarantees. The forward-looking statements made in this release are made only as of the date hereof, and the company disclaims any intention or responsibility for updating predictions or expectations contained in this release.


'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
5. LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
6. LeMaitre Vascular, Inc. Schedules Fourth Quarter Results and Conference Call
7. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
8. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
9. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
10. Pot bellies linked to early signs of cardiovascular disease
11. Air pollution linked to cardiovascular risk indices in healthy young adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... Scotch Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD ... with the treatment of acute or chronic problems, I focus on preventative care with all ... patient. If you have any questions, always feel free to contact my office and my ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: